Bayer Taps New Medical Chief as BlueRock Therapy Earns Rare-Disease Designation on Both Sides of the Atlantic

Bayer appoints Dr. Christoph Koenen as pharma CMO while BlueRock's OpCT-001 gains FDA and EMA orphan-drug status and Ohio campus advances.

Bayer has handed Dr. Christoph Koenen the role of Chief Medical Officer for its pharmaceutical division, effective October 1. Koenen will keep his existing post as head of Clinical Development and Operations while taking on responsibility for the unit's medical and scientific strategy — a dual mandate that signals the company wants tighter alignment between early clinical work and late-stage decision-making.

The appointment lands at a moment when Bayer's pipeline is generating genuine regulatory momentum. Its subsidiary BlueRock Therapeutics secured orphan-drug status from both the FDA and the EMA for lemiretprocel, known internally as OpCT-001, a cell therapy aimed at primary photoreceptor diseases. The designation is reserved for rare conditions and comes with procedural relief along the development path, while also drawing attention to the more experimental corners of Bayer's portfolio.

Ohio Campus Anchors a Broader US Bet

Those pipeline wins sit alongside a far larger capital commitment in North America. Bayer's planned modular pharma campus in New Albany, Ohio carries a price tag of USD 2.2 billion across 200 acres, combining active ingredient manufacturing with finished-drug processing. Production will target oncology, cardiovascular and kidney therapies.

The build-out unfolds in two stages: a first module for pharmaceutical ingredients is slated to start operations in 2031, with a finished-medicines unit following in 2034. Construction itself is expected to support roughly 1,500 building jobs, and once the site is fully operational, about 600 permanent positions will be created.

Ohio Governor Mike DeWine called the project the state's largest-ever international health care investment and a record commitment by a German company in the region. Bayer CEO Bill Anderson described the United States as a pivotal location for both manufacturing and innovation. The spending follows a cell therapy facility that opened in Berkeley in 2023 and brings Bayer's US outlays for pharmaceutical research, development and production to more than USD 7 billion over the past five years, according to DPA.

The political backdrop adds another layer. President Donald Trump attributed investment decisions of this scale to his trade policy, and within the pharma industry, building local production capacity increasingly serves as a hedge against potential import tariffs.

Analysts Keep Their Powder Dry

Equity markets, however, are focused on nearer-term signals. JPMorgan's Richard Vosser reaffirmed an "Overweight" rating on October 1 with a price target of EUR 61, cautioning that early market expectations for the third quarter look too optimistic. He pointed to a timing-related soft patch in the agricultural segment as the main drag. Deutsche Bank Research, per media reports, maintained a "Buy" rating and a EUR 60 target on September 29, arguing that medium-term potential remains intact despite temporary pressures.

Bayer shares closed Friday at EUR 45.02, down 0.6%, leaving the stock up 22% year-to-date but only marginally above its 200-day moving average of EUR 43.09. The third-quarter report is due November 3, 2026.

Away from the quarterly noise, Bayer continues to push on other fronts. The FDA recently accepted the marketing application for Lynkuet under priority review, adding another near-term catalyst as management steers the agricultural business through a demanding stretch.